Eli Lilly and Co will stop testing one of its experimental monoclonal antibody treatments in hospitalized Covid-19 patients after a review of results show it did not seem to be helping them.
The company said late yesterday that it would continue testing the treatment in patients with mild or moderate Covid-19 disease and would continue testing it as part of a dual-antibody therapy.
The monoclonal antibody, called bamlanivimab, was being tested in hospitalized patients in a clinical trial run by the National Institute of Allergy and Infectious Diseases. Based on results reviewed Monday that showed patients weren’t helped by this single antibody treatment, no additional Covid-19 hospitalized patients will get it going forward, Lilly said.
There didn’t appear to be any safety issues.
All the other studies looking at this antibody treatment will continue, Lilly said. There’s a trial looking at the impact this antibody treatment could have on patients who have been recently diagnosed with Covid-19 or who have moderate or mild cases.
There is another trial that is looking at its use in combination with a second monoclonal antibody the company calls etesevimab in that same patient population who are early in the course of their disease. Plus doctors are testing bamlanivimab on its own to prevent Covid-19 infection in residents and staff in long-term care facilities.
In October, Lilly filed a request with the US Food and Drug Administration for emergency use authorization of bamlanivimab in patients with mild to moderate cases.